The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R1 has the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5- c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof； and kits comprising such compounds and salts.The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R1 has the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5- c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof； and kits comprising such compounds and salts. The present invention relates to a polymer comprising: i) at least one repetitive unit (V) having one of the following formulae (T) and ii) at least one repetitive unit (U) having one of the following formulae (S).La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (ver fórmula I) y sales farmacéuticamente aceptables de estos, donde R1 tiene los significados definidos en la presente. La memoria descriptiva también se refiere al uso de compuestos de Fórmula (I) y sales de estos para tratar o prevenir una enfermedad mediada por ATM, incluido el cáncer. La memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden compuestos de tipo imidazo[4,5-c]quinolin-2-ona sustituidos y sales farmacéuticamente aceptables de estos； y kits que comprenden tales compuestos y sales.
